share_log

Senti Biosciences | 10-K: FY2023 Annual Report

Senti Biosciences | 10-K: FY2023 Annual Report

Senti Biosciences | 10-K：2023财年年报
美股SEC公告 ·  03/21 22:21

Moomoo AI 已提取核心信息

Senti Biosciences, a clinical-stage biotechnology company, reported a net loss of $71.1 million for the year ended December 31, 2023, compared to a net loss of $58.2 million for the previous year. The company's cash, cash equivalents, and short-term investments totaled $35.9 million as of December 31, 2023, down from $98.6 million the previous year. Operating expenses for the year were $95.3 million, with research and development expenses accounting for $32.2 million. The company recognized a gain of $21.9 million from the disposal of its Alameda facility to GeneFab, which also resulted in a reduction of longer-term operating expenses. Senti Biosciences has not generated revenue from product sales and anticipates continued significant losses and increased expenses as it advances its gene circuit platform technologies and clinical development of product candidates. The company's future plans include focusing on the clinical development of SENTI-202 and partnering its SENTI-301A program in China with Celest. Senti Biosciences has raised concerns about its ability to continue as a going concern beyond the next twelve months without additional funding.
Senti Biosciences, a clinical-stage biotechnology company, reported a net loss of $71.1 million for the year ended December 31, 2023, compared to a net loss of $58.2 million for the previous year. The company's cash, cash equivalents, and short-term investments totaled $35.9 million as of December 31, 2023, down from $98.6 million the previous year. Operating expenses for the year were $95.3 million, with research and development expenses accounting for $32.2 million. The company recognized a gain of $21.9 million from the disposal of its Alameda facility to GeneFab, which also resulted in a reduction of longer-term operating expenses. Senti Biosciences has not generated revenue from product sales and anticipates continued significant losses and increased expenses as it advances its gene circuit platform technologies and clinical development of product candidates. The company's future plans include focusing on the clinical development of SENTI-202 and partnering its SENTI-301A program in China with Celest. Senti Biosciences has raised concerns about its ability to continue as a going concern beyond the next twelve months without additional funding.
临床阶段的生物技术公司Senti Biosciences报告称，2023年12月31日结束的财年净亏损为7110万美元，而上一年的净亏损为5820万美元。截至2023年12月31日，公司的现金、现金等价物和短期投资总额为3590万美元，低于上一年的9860万美元。该公司今年的营业费用为9530万美元，其中研发费用占到了3220万美元。公司从向GeneFab出售其Alameda工厂中获得了2190万美元的收益，同时也减少了较长期的营业费用。Senti Biosciences尚未从产品销售中产生营业收入，并预计在推进其基因电路平台技术和产品候选人的临床开发时，将继续面临巨额损失和增加的费用。该公司未来的计划包括专注于SENTI-202的临床发展，并与Celest在中国合作其SENTI-301A项目。Senti Biosciences已对其在未来十二个月内没有额外资金支持的持续经营能力提出了担忧。
临床阶段的生物技术公司Senti Biosciences报告称，2023年12月31日结束的财年净亏损为7110万美元，而上一年的净亏损为5820万美元。截至2023年12月31日，公司的现金、现金等价物和短期投资总额为3590万美元，低于上一年的9860万美元。该公司今年的营业费用为9530万美元，其中研发费用占到了3220万美元。公司从向GeneFab出售其Alameda工厂中获得了2190万美元的收益，同时也减少了较长期的营业费用。Senti Biosciences尚未从产品销售中产生营业收入，并预计在推进其基因电路平台技术和产品候选人的临床开发时，将继续面临巨额损失和增加的费用。该公司未来的计划包括专注于SENTI-202的临床发展，并与Celest在中国合作其SENTI-301A项目。Senti Biosciences已对其在未来十二个月内没有额外资金支持的持续经营能力提出了担忧。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间